Abstract
Executive Summary
There is a plethora of new anti-angiogenic drugs in development. The potential
to block tumor growth and metastases by angiogenesis inhibition represents an
intriguing therapeutic strategy for the treatment of cancer and never before
have we seen as many anti-angiogenic drugs in clinical trials.
This report is written for you to identify your competition and understand
which targeting strategies are at work within anti-angiogenic drug development
in oncology. It allows you to pin-point which competitors drugs' clinical
out-come may have bearing on your own drug development and who are developing
sequels to blockbuster drugs. This report also helps you to locate white-spots
in the competitive landscape, giving you little or no competition. Conversly
it may reveal unexpected competition for you. First, BioSeeker has surveyed
anti-angiogenic drugs in oncology and identified 108 drug targets, belonging
to 123drugs. This report, Target Atlas: Competitive Insights to
Anti-Angiogenic Drug R&D in Oncology, is an open landscape of resources to
build, fuel, and drive your scientific competitive vehicle for the advancement
of new anti-angiogenic drugs in oncology.
In the report, BioSeeker reports on 88 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 123 anti-angiogenic drugs designed for the treatment of 44 different
cancer indications. The highest degree of distinctiveness among
anti-angiogenic drugs is achieved by sorting each of them according to
targeted cancer indication, drug target mix, and drug compound type. At the
same time we are also identifying peer groups of drugs, that is, drugs we
consider suitable for head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into
the presence and relevance of protein-protein interactions between identified
targets of anti-angiogenic drugs. No less than 162 protein-protein
interactions were recognized among and between 86 of the 108 included
anti-angiogenic drug targets.
Why You Should Own Your Own Copy of this Report:
- 230+ pages, with almost a hundred different tables and figures. Includes
more than 1,500 active links to related resources on the Internet
- 123 anti-angiogenic drugs, under development by 90 investigators, are
included, covering more than 361 developmental projects in cancer
- 108 Unique, in-depth, drug target profiles, highlighting twelve themes
about the drug target, i.e. protein-protein interaction with other
anti-angiogenic drug targets, linked cancer indications, drugs under
development, compound types, presence in the Cancer Genome Project etc.
- Unique 231 drug-protein target interactome analysis
- Unique drug target combination breakdown into 44 different cancer types
- Covers 88 unique drug target combinations of anti-angiogenic drugs
- 162 protein-protein interactions among and between anti-angiogenic drug
targets
- Pathway grouping of anti-angiogenic drug targets
- Pin-point which competitor drugs' clinical out-come may have bearing on
your own drug development
- Who are working on sequels to blockbuster drugs
- Locate white-spots in the competitive landscape, giving you little or no
competition
In all, this report is a serious reference for any professional interested in
the development of oncology drug targets and the selection/validation of
targeting strategies.
View Cart
